Anthony Conway is Senior Director and Head of Cell Therapy at Replay. He brings over 15 years of cell and gene therapy experience in the pharmaceutical and biotechnology industry and academia.
Anthony joins us most recently from Novo Nordisk's Cell Therapy R&D unit situated within their global R&D headquarters in Denmark, where as Project Director he led a variety of hypoimmunogenic and non-genetically engineered pluripotent stem cell‐derived allogeneic cell therapy programs addressing chronic and acute indications across multiple therapeutic areas. Prior to that he worked at Sangamo Therapeutics for nearly a decade, where he led several genome edited cell and gene therapy programs and teams, including an allogeneic primary CAR-T cell platform eventually licensed to Kite Gilead in the field of oncology. Amongst other things, he built the company’s iPSC-derived Regulatory T cell (Treg) platform and is co-inventor of the first publicly disclosed method to produce mature CD4+ T cells from iPSCs.
He received his PhD in Chemical and Biomolecular Engineering from UC Berkeley where he worked in the laboratory of Professor David Schaffer. His PhD thesis focused on stem cell and biomolecular engineering for neurodegeneration and neurobiology applications. He holds over 15 granted and pending patents and an equal number of peer-reviewed scientific journal publications